Compare Fortive Corporation Common Stock (FTV) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortive Corporation Common Stock vs Repligen Corporation Common Stock — how do they compare? Fortive Corporation Common Stock trades at $57.21 (market cap $17.54B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Fortive Corporation Common Stock is the larger of the two by market cap, and Fortive Corporation Common Stock pays a 0.48% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fortive Corporation Common Stock for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| FTV | RGEN | |
|---|---|---|
Market Cap | $17.54B | $11.14B |
Volume | 1,898,662 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $64.09 | $194.57 |
52-Week Low | $48.49 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $20.67B | $11.02B |
Dividend Yield | 0.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortive Corporation (FTV) trades at $58.07, up 1.22% today, with a neutral technical signal and a consensus analyst price target of $63.33. The stock shows strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue growth is modest, but profitability remains solid with a 12.38% net income margin. Recent news highlights product launches and a dividend increase, while institutional activity includes mixed buying and selling.
The outlook is cautiously positive, supported by raised 2026 guidance and core growth acceleration. Key risks include competitive pressures and macroeconomic headwinds. Analyst sentiment is mixed, with 36.67% buy ratings, but the stock offers potential upside to the consensus target if execution continues to improve.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortive Corporation Common Stock
Fortive provides industrial and healthcare technology solutions. Its products and software support measurement, maintenance, worker safety, instrument sterilization, and clinical workflows.
Read more on FTV →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
